Informatics & Technology Advancements for a Large Number of Customers Presents Market Opportunities
This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The global NGS oncology market is projected to reach $51,783 million in 2032 from 14,828.6 million in 2021, witnessing a CAGR of 12.04% during the forecast period 2022-2032. The growth in the NGS oncology market is expected to be driven by an increasing number of panels or kits, bioinformatics services for computational analysis, and a rising number of open-source free sequencing platform providers offering NGS oncology.
Market Lifecycle Stage
The NGS oncology market is a well-developed market with an integral part of medical decision-making, which aid in acquiring information for a wide range of treatment dissemination, accentuating their criticality in healthcare. The NGS oncology has a critical role in the precision medicine approach, as it ensures the safe and effective application of targeted therapeutics. Most global NGS oncology players offer products encompassing the kits, platforms, and services.
Increasing investments in the R&D for NGS oncology is one of the significant global NGS oncology market opportunities. Several diagnostics and pharmaceutical companies are working collaboratively to adopt next-generation sequencing (NGS) in the field of oncology.
Impact
- The presence of major product and service providers of NGS oncology and services in regions such as North America and Europe significantly impacts the market. For instance, Illumina, Inc. provides an NGS sequencing platform and clinical sequencing bioinformatics services.
- Companies such as Thermo Fisher Scientific Inc. expanded hematology oncology portfolio NGS with new Ion Torrent Oncomine Immune Repertoire Assays that ensure quality results. The presence of these companies has a positive impact on market growth.
Impact of COVID-19
The current global NGS oncology market study comprises next-generation sequencing (NGS)-based products and services for oncology used for diagnosing cancer, measuring cancer risk, and aiding in providing the right and personalized treatment to cancer patients. Since the market is primarily dominated by manufacturers of next-generation sequencing instruments, kits, assays, and service providers that provide gene panels and testing services using next-generation sequencing for oncology, the pandemic negatively impacted the growth of revenue generated from the market. Players in the NGS oncology market reported a decline in revenues during the initial phase of the pandemic. The decrease was primarily attributed to the lockdown in the regions that disrupted the supply chain, thereby hampering the cancer diagnostic testing.
Additionally, a halt in research and development activities pertaining to the use of next-generation sequencing for oncology to discover novel variants and develop novel products and services for the market also led to a decline in revenue. However, to curb the spread of the SARS-CoV-2 virus and contain the spread of the virus, demand for COVID-19 tests and services that detects the virus in less time increased, which led to the shift in focus of the manufacturers and service providers for developing and manufacturing testing kits and services for the detection of SARS-CoV-2 virus.
Market Segmentation
by Sequencing Technology
- Targeted Sequencing
- Genomics
- Transcriptomics
- Epigenomics
The global NGS oncology market (by sequencing technology) is dominated by targeted sequencing in 2021. The segment is expected to maintain its dominance throughout the forecast period 2022-2032. Genomics held the second largest market share, followed by epigenomics and transcriptomics.
by Offering
- Platform
- Kits
- Services
The global NGS oncology market (by offering) is dominated by kits, followed by platform and services. The kits segment is expected to maintain its dominance throughout the forecast period 2022-2032.
by Workflow
- Pre-Sequencing
- Sequencing
- Data Analysis
The global NGS oncology market (by workflow) is dominated by pre-sequencing, followed by sequencing and data analysis. The pre-sequencing segment is expected to maintain its dominance during the forecast period 2022-2032.
by Application
- Genetic Screening
- Hereditary Genetic Testing
- Hematological Malignancies
- Solid Tumors
- Other Applications
The global NGS oncology market (by application) is dominated by hereditary genetic testing, which is expected to maintain its dominance during the forecast period 2022-2032. The solid tumors segment holds the second position in market share, followed by hematological malignancies and genetic screening in 2021.
by End User
- Hospitals and Clinics
- Clinical Research Organizations (CROs)
- Academic and Research Institutes
- Pharmaceutical and Biotechnology Companies
- Other End Users
The global NGS oncology market (by end user) is dominated by hospitals and clinics, followed by pharmaceutical and biotechnology companies. The hospitals and clinics segment is expected to maintain its dominance during the forecast period 2022-2032.
by Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Rest-of-the-World
North America generated the highest revenue of $6,386.9 million in 2021 and dominated the global NGS oncology market. The population of North America suffers from various diseases and rising healthcare costs. The government is extensively supporting research organizations with projects aimed at improving the understanding and treatment of cancer patients.
Recent Developments in the Global NGS Oncology Market
- In October 2021, F. Hoffmann-La Roche Ltd. announced the launch of the AVENIO Tumor Tissue Comprehensive Genomic Profiling (CGP) Kit that allows laboratories to expand their in-house precision cancer research, gain meaningful genomic insights, and enhance their understanding of cancer biology. The kit is the first co-developed product by F. Hoffmann-La Roche Ltd. and Foundation Medicine, bringing in the expertise of both companies in genomic science. With the launch of the kit, the company anticipates significant expansion in access to genomic profiling globally and strengthens the company's ability to act as an essential partner to researchers working on cancer care.
- In September 2021, Thermo Fisher Scientific Inc. introduced the Applied Biosystems QuantStudio Absolute Q Digital PCR System, the first fully integrated digital PCR (dPCR) system designed to deliver highly accurate and consistent results in 90 minutes, excels in cancer research and other fields.
- In September 2020, Agilent Technologies, Inc. launched a product new Agilent SureSelect XT HS2 DNA Kit designed to address challenges faced by researchers while preparing DNA sequencing libraries. The kit represents state-of-art library preparation and target enrichment.
Demand - Drivers and Limitations
Following are the demand drivers for the global NGS Oncology Market:
- Increasing Incidence of Cancer Requiring Sophisticated Molecular Techniques
- Reducing Cost of Sequencing
- Rapid Technological Advancements Related to NGS Oncology
The market is expected to face some limitations too due to the following challenges:
- Inadequate NGS Oncology Reimbursement Scenario
- Increasing Cost of NGS Automated Sample Preparation Instruments
- Barriers in the Advancement of NGS Oncology
How Can This Report Add Value to an Organization?
Product/Innovation Strategy: Major manufacturers of the global NGS oncology market, along with the service providers, are actively involved in undertaking significant business strategies to translate success in research and development into the commercial clinical setting.
Growth/Marketing Strategy: Owing to the explosion of massively parallel sequencing and its applications, all areas of medicine have been affected, particularly oncology. NGS sequencing has gradually evolved from conventional sequencing to a fully integrated digital PCR (dPCR) system designed to deliver extremely accurate and consistent results in 90 minutes, which excels in cancer research and other fields.
Competitive Strategy: Key players in the global NGS oncology market analyzed and profiled in the study have been involved as the NGS oncology-based product and services manufacturers that provide kits or panel and software services. Moreover, a detailed competitive benchmarking of the players operating in the global NGS oncology market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
Some prominent names established in this market are:
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Biodesix, Inc.
- Caris Life Sciences
- DNASTAR
- Fulgent Genetics, Inc.
- F. Hoffmann-La Roche Ltd
- Illumina, Inc.
- Invitae Corporation
- IntegraGen (OncoDNA)
- Oxford Nanopore Technologies plc.
- Pacific Biosciences of California, Inc.
- PerkinElmer, Inc.
- Pillar Biosciences, Inc.
- QIAGEN N.V.
- Thermo Fisher Scientific Inc.
- Takara Bio Inc.
- Vela Diagnostics
Table of Contents
1 Markets
1.1 Product Definition
1.1.1 Inclusion and Exclusion Criteria
1.2 Market Scope
1.2.1 Scope of the Study
1.2.2 Key Questions Answered in the Report
1.3 Research Methodology
1.3.1 Global NGS Oncology Market: Research Methodology
1.3.2 Data Sources
1.3.2.1 Primary Data Sources
1.3.2.2 Secondary Data Sources
1.3.3 Market Estimation Model
1.3.4 Criteria for Company Profiling
1.4 Global NGS Oncology Market: Overview
1.4.1 Market Size and Growth Potential, $Million, 2021-2032
1.4.2 COVID-19 Impact on Global NGS Oncology Market
1.5 Global NGS Oncology Market: Patent Landscape
1.5.1 Patent Filing Trend
1.5.2 Patent Analysis (by Year)
1.5.3 Patent Analysis (by Region)
1.5.4 Patent Analysis (by Country)
2 Industry Analysis
2.1 Overview
2.2 Regulatory Framework in the U.S.
2.2.1 FDA Regulation
2.2.2 Centers for Medicaid and Medicare Services (CMS) Regulation
2.3 Regulatory Framework in European Union (EU)
2.4 Regulatory Framework in Asia-Pacific
2.4.1 China
2.4.2 Japan
3 Market Dynamics
3.1 Market Dynamics
3.1.1 Overview
3.2 Impact Analysis
3.3 Market Drivers
3.3.1 Increasing Incidence of Cancer Requiring Sophisticated Molecular Techniques
3.3.2 Reducing Cost of Sequencing
3.3.3 Rapid Technological Advancements Related to NGS Oncology
3.4 Market Challenges
3.4.1 Inadequate NGS Oncology Reimbursement Scenario
3.4.2 Increasing Cost of NGS Automated Sample Preparation Instruments
3.4.3 Barriers in the Advancement of NGS Oncology
3.5 Market Opportunities
3.5.1 Informatics and Technology Advancement for A Large Number of Customers
3.5.2 Rising Number of Initiatives for NGS Oncology Research
4 Competitive Landscape
4.1 Overview
4.2 Corporate Strategies
4.2.1 Mergers and Acquisitions
4.2.2 Synergistic Activities
4.2.3 Business Expansion and Funding Activities
4.3 Business Strategies
4.3.1 Product Launches/Approvals
4.3.2 Product Upgradation
4.4 Market Share Analysis (by Company)
4.5 Growth-Share Analysis (by Application)
5 Offerings, $Million, 2021-2032
5.1 Overview
5.1.1 Platform
5.1.2 Kits
5.1.3 Services
6 Sequencing Technology, $Million, 2021-2032
6.1 Overview
6.1.1 Targeted Sequencing
6.1.2 Genomics
6.1.2.1 Whole-Genome Sequencing (WGS)
6.1.2.2 Whole-Exome Sequencing (WES)
6.1.3 Transcriptomics
6.1.4 Epigenomics
6.1.4.1 ChIP-Sequencing (ChIP-Seq)
6.1.4.2 Bisulfite Sequencing
7 Workflow, $Million, 2021-2032
7.1 Overview
7.1.1 Pre-Sequencing
7.1.1.1 Sample Extraction/Isolation
7.1.1.2 Library Preparation
7.1.1.3 Target Enrichment
7.1.2 Sequencing
7.1.3 Data Analysis
7.1.3.1 Secondary Analysis
7.1.3.2 Tertiary Analysis
8 Applications, $Million, 2021-2032
8.1 Overview
8.2 Genetic Screening
8.3 Hereditary Genetic Testing
8.4 Hematological Malignancies
8.4.1 Leukemia
8.4.2 Lymphoma
8.4.3 Multiple Myeloma
8.4.4 Other Hematological Malignancies
8.5 Solid Tumors
8.5.1 Breast Cancer
8.5.2 Lung Cancer
8.5.3 Colorectal Cancer
8.5.4 Prostate Cancer
8.5.5 Thyroid Cancer
8.5.6 Endometrial Cancer
8.5.7 Lymphoma
8.5.8 Melanoma
8.5.9 Brain Cancer
8.5.10 Other Solid Tumors
8.6 Other Applications
9 End Users, $Million, 2021-2032
9.1 Overview
9.2 Hospitals and Clinics
9.3 Clinical Research Organizations (CROs)
9.4 Academic and Research Institutes
9.5 Pharmaceutical and Biotechnology Companies
9.6 Other End Users
10 Regions, $Million, 2021-2032
10.1 Overview
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 France
10.3.3 U.K.
10.3.4 Italy
10.3.5 Netherlands
10.3.6 Spain
10.3.7 Rest-of-Europe
10.4 Asia-Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Singapore
10.4.7 Rest-of-Asia-Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest-of-Latin America
10.6 Rest-of-the-World
11 Company Profiles
11.1 Overview
11.2 Agilent Technologies, Inc.
11.2.1 Company Overview
11.2.2 Role of Agilent Technologies, Inc. in the Global NGS Oncology Market
11.2.3 Key Customers of the Company
11.2.4 Key Competitors of the Company
11.2.5 Financials
11.2.6 Key Insights about the Financial Health of the Company
11.2.7 Corporate Strategies
11.2.7.1 Mergers and Acquisitions
11.2.7.2 Business Expansion and Funding
11.2.8 Business Strategies
11.2.8.1 Agilent Technologies, Inc.: Product Launch/Approval
11.2.9 Analyst Perspective
11.3 Bio-Rad Laboratories, Inc.
11.3.1 Company Overview
11.3.2 Role of Bio-Rad Laboratories, Inc. in the Global NGS Oncology Market
11.3.3 Key Customers of the Company
11.3.4 Key Competitors of the Company
11.3.5 Financials
11.3.6 Key Insights about the Financial Health of the Company
11.3.7 Business Strategies
11.3.7.1 Product Launch/ Approval
11.3.8 Analyst Perspective
11.4 Biodesix, Inc.
11.4.1 Company Overview
11.4.2 Role of Biodesix, Inc. in the Global NGS Oncology Market
11.4.3 Key Customers of the Company
11.4.4 Key Competitors of the Company
11.4.5 Financials
11.4.6 Key Insights about the Financial Health of the Company
11.4.7 Corporate Strategies
11.4.7.1 Synergistic Activities
11.4.8 Analyst Perspective
11.5 Caris Life Sciences
11.5.1 Company Overview
11.5.2 Role of Caris Life Sciences in the Global NGS Oncology Market
11.5.3 Key Customers of the Company
11.5.4 Key Competitors of the Company
11.5.5 Analyst Perspective
11.6 DNASTAR
11.6.1 Company Overview
11.6.2 Role of DNASTAR in the Global NGS Oncology Market
11.6.3 Key Customers of the Company
11.6.4 Key Competitors of the Company
11.6.5 Corporate Strategies
11.6.5.1 Mergers and Acquisitions
11.6.6 Business Strategies
11.6.6.1 Product Launch/Approval
11.6.7 Analyst Perspective
11.7 Fulgent Genetics, Inc.
11.7.1 Company Overview
11.7.2 Role of Fulgent Genetics, Inc. in the Global NGS Oncology Market
11.7.3 Key Customers of the Company
11.7.4 Key Competitors of the Company
11.7.5 Financials
11.7.6 Key Insights about the Financial Health of the Company
11.7.7 Corporate Strategies
11.7.7.1 Business Expansion
11.7.8 Analyst Perspective
11.8 F. Hoffmann-La Roche Ltd
11.8.1 Company Overview
11.8.2 Role of F. Hoffmann-La Roche Ltd in the Global NGS Oncology Market
11.8.3 Key Customers of the Company
11.8.4 Key Competitors of the Company
11.8.5 Financials
11.8.6 Key Insights about the Financial Health of the Company
11.8.7 Corporate Strategies
11.8.7.1 Synergistic Activities
11.8.8 Business Strategies
11.8.8.1 Product Launch
11.8.9 Analyst Perspective
11.9 Illumina, Inc.
11.9.1 Company Overview
11.9.2 Role of Illumina, Inc. in the Global NGS Oncology Market
11.9.3 Key Customers of the Company
11.9.4 Key Competitors of the Company
11.9.5 Financials
11.9.6 Key Insights about the Financial Health of the Company
11.9.7 Corporate Strategies
11.9.7.1 Synergistic Activities
11.9.8 Analyst Perspective
11.10 Invitae Corporation
11.10.1 Company Overview
11.10.2 Role of Invitae Corporation in the Global NGS Oncology Market
11.10.3 Key Customers of the Company
11.10.4 Key Competitors of the Company
11.10.5 Financials
11.10.6 Key Insights about the Financial Health of the Company
11.10.7 Business Strategies
11.10.7.1 Product Launch
11.10.8 Analyst Perspective
11.11 IntegraGen (OncoDNA)
11.11.1 Company Overview
11.11.2 Role of IntegraGen (OncoDNA) in the Global NGS Oncology Market
11.11.3 Key Customers of the Company
11.11.4 Key Competitors of the Company
11.11.5 Business Strategies
11.11.5.1 Product Launch/ Approval
11.11.6 Analyst Perspective
11.12 Oxford Nanopore Technologies plc.
11.12.1 Company Overview
11.12.2 Role of Oxford Nanopore Technologies plc. in the Global NGS Oncology Market
11.12.3 Key Customers of the Company
11.12.4 Key Competitors of the Company
11.12.5 Financials
11.12.6 Key Insights about the Financial Health of the Company
11.12.7 Corporate Strategies
11.12.7.1 Synergistic Activities
11.12.8 Business Strategies
11.12.8.1 Product Launch/ Approval
11.12.9 Analyst Perspective
11.13 Pacific Biosciences of California, Inc.
11.13.1 Company Overview
11.13.2 Role of Pacific Biosciences of California, Inc. in the Global NGS Oncology Market
11.13.3 Key Customers of the Company
11.13.4 Key Competitors of the Company
11.13.5 Financials
11.13.6 Key Insights about the Financial Health of the Company
11.13.7 Corporate Strategies
11.13.7.1 Mergers and Acquisitions
11.13.7.2 Synergistic Activities
11.13.8 Analyst Perspective
11.14 PerkinElmer, Inc.
11.14.1 Company Overview
11.14.2 Role of PerkinElmer, Inc. in the Global NGS Oncology Market
11.14.3 Key Customers of the Company
11.14.4 Key Competitors of the Company
11.14.5 Financials
11.14.6 Key Insights about the Financial Health of the Company
11.14.7 Analyst Perspective
11.15 Pillar Biosciences, Inc.
11.15.1 Company Overview
11.15.2 Role of Pillar Biosciences, Inc., in the Global NGS Oncology Market
11.15.3 Key Customers of the Company
11.15.4 Key Competitors of the Company
11.15.5 Corporate Strategies
11.15.5.1 Synergistic Activities
11.15.6 Business Strategies
11.15.6.1 Product Launch/Approval
11.15.7 Analyst Perspective
11.16 QIAGEN N.V.
11.16.1 Company Overview
11.16.2 Role of QIAGEN N.V. in the Global NGS Oncology Market
11.16.3 Key Customers of the Company
11.16.4 Key Competitors of the Company
11.16.5 Financials
11.16.6 Key Insights about the Financial Health of the Company
11.16.7 Corporate Strategies
11.16.7.1 Synergistic Activities
11.16.8 Business Strategies
11.16.8.1 Product Launch/Approvals
11.16.9 Analyst Perspective
11.17 Thermo Fisher Scientific Inc.
11.17.1 Company Overview
11.17.2 Role of Thermo Fisher Scientific Inc. in the Global NGS Oncology Market
11.17.3 Customers of the Company
11.17.4 Key Competitors of the Company
11.17.5 Financials
11.17.6 Key Insights about the Financial Health of the Company
11.17.7 Corporate Strategies
11.17.7.1 Mergers and Acquisitions
11.17.7.2 Synergistic Activities
11.17.7.3 Business Expansion and Funding
11.17.8 Business Strategies
11.17.8.1 Product Launch/Approval
11.17.9 Analyst Perspective
11.18 Takara Bio Inc.
11.18.1 Company Overview
11.18.2 Role of Takara Bio Inc. in the Global NGS Oncology Market
11.18.3 Key Customers of the Company
11.18.4 Key Competitors of the Company
11.18.5 Financials
11.18.6 Key Insights about the Financial Health of the Company
11.18.7 Analyst Perspective
11.19 Vela Diagnostics
11.19.1 Company Overview
11.19.2 Role of Vela Diagnostics in the Global NGS Oncology Market
11.19.3 Key Customers of the Company
11.19.4 Key Competitors of the Company
11.19.5 Business Strategies
11.19.5.1 Product Launch/ Approval
11.19.6 Analyst Perspective
List of Tables
Table 1: Impact Analysis of Market Drivers, Challenges, and Opportunities on the Global NGS Oncology Market
Table 2: Companies Offering Products and Services Using NGS for Hereditary Genetic Testing
Table 3: NGS Approach for B and T-Acute Lymphoblastic Leukemia (ALL)
Table 4: NGS-Based Oncology Panel Test
List of Figures
Figure 1: Global NGS Oncology Market, $Million, 2021 and 2032
Figure 2: Impact Analysis of Market Drivers and Challenges on the Global NGS Oncology Market
Figure 3: Global NGS Oncology Market Segmentation
Figure 4: Global NGS Oncology Market Share (by Sequencing Technology), $Million, 2021 and 2032
Figure 5: Global NGS Oncology Market Share (by Workflow), $Million, 2021 and 2032
Figure 6: Global NGS Oncology Market Share (by Application), $Million, 2021 and 2032
Figure 7: Global NGS Oncology Market Share (by End User), $Million, 2021 and 2032
Figure 8: Global NGS Oncology Market Snapshot (by Region), 2021
Figure 9: Global NGS Oncology Market Segmentation
Figure 10: Global NGS Oncology Market: Research Methodology
Figure 11: Primary Research Methodology
Figure 12: Bottom-Up Approach (Segment-Wise Analysis)
Figure 13: Top-Down Approach (Segment-Wise Analysis)
Figure 14: Global NGS Oncology Market, $Million, 2021-2032
Figure 15: Impact of COVID-19 on the Global NGS Oncology Market
Figure 16: Year-Wise Analysis of Patents Related to NGS Oncology, January 2019-January 2022
Figure 17: Region-Wise Analysis of Patents Related to NGS Oncology, January 2019-January 2022
Figure 18: Country-Wise Analysis of Patents Related to NGS Oncology, January 2019-January 2022
Figure 19: Overview of Regulatory Process for Medical Devices by the FDA
Figure 20: Europe’s IVD Regulatory Approval Process
Figure 21: Medical Device Regulatory Approval Process in China
Figure 22: Global NGS Oncology Market Dynamics
Figure 23: Global Cancer Incidence 2017- 2021
Figure 24: Reducing Cost and Increasing Output (TB) of Genome Sequencing (2009-2025)
Figure 25: Reportable Barriers in the Advancement of Global NGS Oncology Market
Figure 26: Share of Key Development Activities, January 2019-January 2022
Figure 27: Share of Mergers and Acquisitions (by Company), January 2019-January 2022
Figure 28: Share of Synergistic Activities (by Company), January 2019-January 2022
Figure 29: Share of Business Expansion and Funding Activities (by Company), January 2019- January 2022
Figure 30: Share of Product Launches/Approvals (by Company), January 2019-January 2022
Figure 31: Share of Product Upgradation (by Company), January 2019-January 2022
Figure 32: Market Share Analysis of Global NGS Oncology Market (by Company), 2021
Figure 33: Growth-Share Analysis of Global NGS Oncology Market (by Application), 2022-2032
Figure 34: Global NGS Oncology Market (by Offering)
Figure 35: Global NGS Oncology Market (by Offering), $Million, 2021 and 2032
Figure 36: Global NGS Oncology Market (Platform), $Million, 2021-2032
Figure 37: Global NGS Oncology Market (Kits), $Million, 2021-2032
Figure 38: Global NGS Oncology Market (Services), $Million, 2021-2032
Figure 39: Global NGS Oncology Market (by Sequencing Technology)
Figure 40: Global NGS Oncology Market (by Sequencing Technology), $Million, 2021 and 2032
Figure 41: Global NGS Oncology Market (Targeted Sequencing), $Million, 2021-2032
Figure 42: Global NGS Oncology Market (Genomics), $Million, 2021-2032
Figure 43: Global NGS Oncology Market (Whole-Genome Sequencing), $Million, 2021-2032
Figure 44: Global NGS Oncology Market (Whole-Exome Sequencing), $Million, 2021-2032
Figure 45: Global NGS Oncology Market (Transcriptomics), $Million, 2021-2032
Figure 46: Global NGS Oncology Market (Epigenomics), $Million, 2021-2032
Figure 47: Global NGS Oncology Market (ChIP-Sequencing), $Million, 2021-2032
Figure 48: Global NGS Oncology Market (Bisulfite Sequencing), $Million, 2021-2032
Figure 49: Global NGS Oncology Market (by Workflow)
Figure 50: Global NGS Oncology Market (by Workflow), $Million, 2021 and 2032
Figure 51: Global NGS Oncology Market (Pre-Sequencing), $Million, 2021-2032
Figure 52: Global NGS Oncology Market (Sample Extraction/Isolation), $Million, 2021-2032
Figure 53: General Workflow of Next-Generation Sequencing Library Preparation
Figure 54: Global NGS Oncology Market (Library Preparation), $Million, 2021-2032
Figure 55: Different Types of Target Enrichment Techniques
Figure 56: Global NGS Oncology Market (Target Enrichment), $Million, 2021-2032
Figure 57: Global NGS Oncology Market (Sequencing), $Million, 2021-2032
Figure 58: Global NGS Oncology Market (Data Analysis), $Million, 2021-2032
Figure 59: Global NGS Oncology Market (Secondary Analysis), $Million, 2021-2032
Figure 60: Global NGS Oncology Market (Tertiary Analysis), $Million, 2021-2032
Figure 61: Global NGS Oncology Market (by Application), $Million, 2021 and 2032
Figure 62: Challenges Faced Using NGS in Genetic Screening
Figure 63: Global NGS Oncology Market (Genetic Screening), $Million, 2021-2032
Figure 64: Global NGS Oncology Market (Hereditary Genetic Testing), $Million, 2021-2032
Figure 65: Global NGS Oncology Market (Hematological Malignancies), $Million, 2021-2032
Figure 66: Global NGS Oncology Market (Leukemia) $Million, 2021-2032
Figure 67: Global NGS Oncology Market (Lymphoma), $Million, 2021-2032
Figure 68: Global NGS Oncology Market (Multiple Myeloma), $Million, 2021-2032
Figure 69: Global NGS Oncology Market (Other Hematological Malignancies), $Million, 2021-2032
Figure 70: Global NGS Oncology Market (Solid Tumors), $Million, 2021-2032
Figure 71: Global NGS Oncology Market (Breast Cancer), $Million, 2021-2032
Figure 72: Global NGS Oncology Market (Lung Cancer), $Million, 2021-2032
Figure 73: Global NGS Oncology Market (Colorectal Cancer), $Million, 2021-2032
Figure 74: Global NGS Oncology Market (Prostate Cancer), $Million, 2021-2032
Figure 75: Global NGS Oncology Market (Thyroid Cancer), $Million, 2021-2032
Figure 76: Global NGS Oncology Market (Endometrial Cancer), $Million, 2021-2032
Figure 77: Global NGS Oncology Market (Lymphoma), $Million, 2021-2032
Figure 78: Global NGS Oncology (Melanoma), $Million, 2021-2032
Figure 79: Global NGS Oncology Market (Brain Cancer), $Million, 2021-2032
Figure 80: Global NGS Oncology Market (Other Solid Tumors), $Million, 2021-2032
Figure 81: Global NGS Oncology Market (Other Applications), $Million, 2021-2032
Figure 82: Global NGS Oncology Market (by End User), $Million, 2021- 2032
Figure 83: Global NGS Oncology Market (Hospitals and Clinics), $Million, 2021-2032
Figure 84: Global NGS Oncology Market (Clinical Research Organizations), $Million, 2021-2032
Figure 85: Global NGS Oncology Market (Academic and Research Institutes), $Million, 2021-2032
Figure 86: Global NGS Oncology Market (Pharmaceutical and Biotechnology Companies), $Million, 2021-2032
Figure 87: Global NGS Oncology Market (Other End Users), $Million, 2021-2032
Figure 88: Global NGS Oncology Market Snapshot (by Region), $Million, 2021
Figure 89: Global NGS Oncology Market Share (by Region), $Million, 2021 and 2032
Figure 90: Global NGS Oncology Market (North America), $Million, 2021-2032
Figure 91: U.S. NGS Oncology Market, $Million, 2021-2032
Figure 92: Canada NGS Oncology Market, $Million, 2021-2032
Figure 93: Europe NGS Oncology Market, $Million, 2021-2032
Figure 94: Europe NGS Oncology Market Share (by Country), $Million, 2021 and 2032
Figure 95: Germany NGS Oncology Market, $Million, 2021-2032
Figure 96: France NGS Oncology Market, $Million, 2021-2032
Figure 97: U.K. NGS Oncology Market, $Million, 2021-2032
Figure 98: Italy NGS Oncology Market, $Million, 2021-2032
Figure 99: Netherlands NGS Oncology Market, $Million, 2021-2032
Figure 100: Spain NGS Oncology Market, $Million, 2021-2032
Figure 101: Rest-of-Europe NGS Oncology Market, $Million, 2021-2032
Figure 102: Asia-Pacific NGS Oncology Market, $Million, 2021-2032
Figure 103: Asia-Pacific NGS Oncology Market Share (by Country), $Million, 2021 and 2032
Figure 104: China NGS Oncology Market, $Million, 2021-2032
Figure 105: Japan NGS Oncology Market, $Million, 2021-2032
Figure 106: India NGS Oncology Market, $Million, 2021-2032
Figure 107: Australia NGS Oncology Market, $Million, 2021-2032
Figure 108: South Korea NGS Oncology Market, $Million, 2021-2032
Figure 109: Singapore NGS Oncology Market, $Million, 2021-2032
Figure 110: Rest-of-Asia-Pacific (RoAPAC) NGS Oncology Market, $Million, 2021-2032
Figure 111: Latin America NGS Oncology Market, $Million, 2021-2032
Figure 112: Latin America NGS Oncology Market Share (by Country), $Million, 2021 and 2032
Figure 113: Brazil NGS Oncology Market, $Million, 2021-2032
Figure 114: Mexico NGS Oncology Market, $Million, 2021-2032
Figure 115: Rest-of-Latin America NGS Oncology Market, $Million, 2021-2032
Figure 116: Rest-of-the-World NGS Oncology Market, $Million, 2021-2032
Figure 117: Total Number of Companies Profiled
Figure 118: Global NGS Oncology Market: Company Profile Overview
Figure 119: Agilent Technologies, Inc.: Product Portfolio
Figure 120: Agilent Technologies, Inc.: Overall Financials, $Million, 2019-2021
Figure 121: Agilent Technologies, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 122: Agilent Technologies, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 123: Agilent Technologies, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 124: Bio-Rad Laboratories, Inc.: Product Portfolio
Figure 125: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2019-2021
Figure 126: Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 127: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 128: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 129: Biodesix, Inc.: Product Portfolio
Figure 130: Biodesix, Inc.: Overall Financials, $Million, 2019-2021
Figure 131: Biodesix, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 132: Biodesix, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 133: Caris Life Sciences: Product Portfolio
Figure 134: DNASTAR: Product Portfolio
Figure 135: Fulgent Genetics, Inc.: Product Portfolio
Figure 136: Fulgent Genetics, Inc.: Overall Financials, $Million, 2019-2021
Figure 137: Fulgent Genetics, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 138: Fulgent Genetics, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 139: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 140: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2019-2021
Figure 141: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2019-2021
Figure 142: F. Hoffmann-La Roche Ltd: Revenue (by Region), $Million, 2019-2021
Figure 143: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2019-2021
Figure 144: Illumina, Inc.: Product Portfolio
Figure 145: Illumina, Inc.: Overall Financials, $Million, 2019-2021
Figure 146: Illumina, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 147: Illumina, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 148: Illumina, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 149: Invitae Corporation: Product/Service Portfolio
Figure 150: Invitae Corporation: Overall Financials, $Million, 2019-2021
Figure 151: Invitae Corporation: Revenue (by Segment), $Million, 2019-2021
Figure 152: Invitae Corporation: Revenue (by Region), $Million, 2019-2021
Figure 153: Invitae Corporation: R&D Expenditure, $Million, 2019-2021
Figure 154: IntegraGen (OncoDNA): Product Portfolio
Figure 155: Oxford Nanopore Technologies plc.: Product Portfolio
Figure 156: Oxford Nanopore Technologies plc.: Overall Financials, $Million, 2018-2020
Figure 157: Oxford Nanopore Technologies plc.: Revenue (by Segment), $Million, 2018-2020
Figure 158: Oxford Nanopore Technologies plc.: Revenue (by Region), $Million, 2018-2020
Figure 159: Oxford Nanopore Technologies plc.: R&D Expenditure, $Million, 2018-2020
Figure 160: Pacific Biosciences of California, Inc.: Product Portfolio
Figure 161: Pacific Biosciences of California, Inc.: Overall Financials, $Million, 2019-2021
Figure 162: Pacific Biosciences of California, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 163: Pacific Biosciences of California, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 164: Pacific Biosciences of California, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 165: PerkinElmer, Inc.: Product Portfolio
Figure 166: PerkinElmer, Inc.: Overall Financials, $Million, 2019-2021
Figure 167: PerkinElmer, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 168: PerkinElmer, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 169: PerkinElmer, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 170: Pillar Biosciences, Inc.: Product Portfolio
Figure 171: QIAGEN N.V.: Product Portfolio
Figure 172: QIAGEN N.V.: Overall Financials, $Million, 2019-2021
Figure 173: QIAGEN N.V.: Revenue (by Segment), $Million, 2019-2021
Figure 174: QIAGEN N.V.: Revenue (by Region), $Million, 2019-2021
Figure 175: QIAGEN N.V.: R&D Expenditure, $Million, 2019-2021
Figure 176: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 177: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2019-2021
Figure 178: Thermo Fisher Scientific Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 179: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2019-2021
Figure 180: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2019-2021
Figure 181: Takara Bio Inc.: Product Portfolio
Figure 182: Takara Bio Inc.: Overall Financials, $Million, 2018-2020
Figure 183: Takara Bio Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 184: Takara Bio Inc.: Revenue (by Region), $Million, 2018-2020
Figure 185: Takara Bio Inc.: R&D Expenditure, $Million, 2018-2020
Figure 186: Vela Diagnostics: Product Portfolio
Companies Mentioned
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Biodesix, Inc.
- Caris Life Sciences
- DNASTAR
- Fulgent Genetics, Inc.
- F. Hoffmann-La Roche Ltd
- Illumina, Inc.
- Invitae Corporation
- IntegraGen (OncoDNA)
- Oxford Nanopore Technologies plc.
- Pacific Biosciences of California, Inc.
- PerkinElmer, Inc.
- Pillar Biosciences, Inc.
- QIAGEN N.V.
- Thermo Fisher Scientific Inc.
- Takara Bio Inc.
- Vela Diagnostics
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 257 |
| Published | June 2022 |
| Forecast Period | 2022 - 2032 |
| Estimated Market Value ( USD | $ 16618.4 Million |
| Forecasted Market Value ( USD | $ 51783 Million |
| Compound Annual Growth Rate | 12.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 18 |
